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Chemotherapeutic agents capable of inhibiting
cellular replication are becoming increasingly
useful in the treatment of non-neoplastic diseases
of the skin. The use of podophyllin in the topical
therapy of condylomata acuminata is one of the
earliest examples of the value of growth-inhibitors
in dermatology. This resinous substance sup-
presses growth by arresting the mitotic process
in a similar manner to colchicine (1). Both derma-
tologic and systemic manifestations of certain
disorders associated with hypersensitivity re-
spond to the immunosuppressive properties of
alkylating agents and antimetabolites even when
treatment with corticosteroids has been unsuc-
cessful (2, 3, 4). Infections caused by some DNA
viruses, notably herpes simplex and vaceinia,
are inhibited by 5-iodo-2'-deoxyuridine (IUdR)
(5), an antimetabolite that interferes with the
incorporation of thymidine into DNA (6). Con-
siderable effort is being directed towards the
development of dermatologic preparations of this
agent for the treatment of these and related
viral infections of the skin (7, 8, 9).
The beneficial effects of the folic acid antago-
nists in the treatment of psoriasis have been
known for the past 13 years (10). Only recently,
however, was the nature of this effect clearly
attributed, by Van Scott and Reinerton, to an
inhibition of cellular reproduction which is
markedly increased in psoriatic lesions (11).
These investigators have compared other anti-
neoplastic agents with diverse cytotoxic prop-
crties to the antifolates, methotrexate and amin-
opterin, for their effect on psoriatic epidermis.
Improvement of the skin lesions was always
associated with a decrease in the mitotic activity
of the epidermis thereby restoring its ability to
* From the Sections of Dermatology and Clini-
cal Pharmacology, Departments of Internal Medi-
cine and Pharmacology, Yale University School
of Medicine, New Haven, Connecticut.
Presented at the Twenty-fifth Annual Meeting
of The Society for Investigative Dermatology,
Inc., San Francisco, Calif., June 23, 1964.
Supported in part by P.H.S. Grants Nos. CA-
05944, CA-5138 and MO-IFR-38.
Public Health Service Special Fellow (IF
3-AM-24,279-01).
Recipient, Burroughs Wellcome Fund Clinical
Pharmacology Award.
551
produce normal-appearing keratin. Similar re-
sults were associated with clinical improvement
regardless of the drug employed.
Aminopterin or methotrexate are frequently
used when more conservative, topical forms of
treatment are not effective in severe cases of
psoriasis. These agents compete with folic acid
for folio reduetase, blocking the formation of
tetrahydrofolic acid, a component of numerous
essential coenzymes (12). Since all cells depend
upon the products of tetrahydrofolate formation,
all are susceptible to the antimetabolic effects
of the folic antagonists, but those with high
mitotic activity are suppressed earlier than
others with a slower turnover.
Unfortunately, the full potential of the folio
acid antagonists cannot always be utilized in the
treatment of psoriasis. Untoward reactions of
these drugs involving other tissues may accom-
pany the use of the most advantageous doses
(10), and prolonged administration results in
cumulative effects (12, 13). Because of these
drawbacks it was considered worthwhile to in-
vestigate the response of patients with severe
psoriasis to 6-azauridine (AzUR), a newer anti-
metabolite capable of inhibiting growth of certain
neoplastic cells without comparable toxicity to
normal cells in man (14).
The following is a report of the observations
in 10 individuals with extensive, resistant psoria-
sis treated with triacetyl AzUR (TA-AzUR); a
preliminary report of trials with TA-AzUR in
psoriasis and mycosis fungoides has been pre-
sented (15).
METHODS
Ten patients with severe, disabling psoriasis,
4 with exfoliative erythroderma and 6 with exten-
sive plaque-like disease, were hospitalized at the
Grace-New Haven Community Hospital for initia-
tion of treatment with TA-AzUR. These included
4 women and 6 men whose ages ranged from 30 to
SO years. No other specific treatment for psoriasis
was used for at least 4 weeks prior to hospitaliza-
tion or during treatment with TA-AzUR.
The drug was administered orally as the tn-
acetyl derivative since, in contrast to free AzUR,
it is rapidly absorbed from the gastrointestinal
tract and results in more prolonged levels of
AzUR in the circulation (16, 17). All patients were
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treated with an initial dose of 270 mg/kg/day.
After 10 to 20 days, the dose was reduced to 135
mg/kg/day. Two patients received 70 mg/kg/day
for several weeks. The medication was supplied in
gelatin capsules containing 500 mg of the drug and
the daily dose was administered in 3 equal portions
every S hours. The length of each course of treat-
ment was governed by the clinical response of the
skin lesions and varied between 10 days and 7
months. Therapy was continuous except for oc-
casional interruptions of 1 to 2 weeks in some
patients. Six individuals are still on therapy after
7,0,5,4, 2 and 14 months, respectively.
The following determinations were carried out
in all patients before beginning treatment: hcma-
tocrit, total and differential leukocyte counts,
reticulocyte and platelet counts, serum uric acid
and serum iron. These examinations were repeated
at 3 to 4 day intervals during the first 3 weeks of
therapy, and at weekly or biweekly intervals
thereafter. Serial biopsies of representative pso-
riatic lesions were performed twice weekly in 5
patients before and during the first 6 weeks of
treatment. Microscopic examination of scalp hair
roots was carried out in 4 patients at different
intervals from initiation of therapy. Bone marrow
aspirations were performed in 9 patients, and the
rate of disappearance of Fe59 from the plasma
was measured in 4 subjects on treatment. Electro-
encephalograms, liver function tests and blood
urea nitrogen determinations were obtained in
several patients before and at varying intervals
after initiation of therapy.
FIG. 1. 65-year-old white man with exfoliative crythrodormic psoriasis of S weeks' duration: (a)
before treatment, (b) after 14 days of treatment with TA-AzIJI4.
RESULTS
Clinical Observations
All patients showed clinical improvement of
their skin lesions. The rate of this change ap-
peared to depend more upon the thickness rather
than upon the extent of the original lesions. The
first signs of improvement, however, were ob-
served at about the same interval of time follow-
ing initiation of drug therapy, regardless of the
character of the lesions. By the second day of
treatment, erythcma and scaling were noticeably
diminished, particularly in the center of the
localized plaques. Thereafter, the rate of resolu-
tion varied among the subjects. The most rapid
improvement was seen in the 4 patients with
exfoliative erythroderma. Excluding a faintly
dusky residual erythema, no evidence of skin
involvement was discernible after the first 7 to 10
days of treatment (Figure 1). In the 6 individuals
with plaque-like disease, the lesions in 3 cleared
completely after 2 to 7 months of therapy, and
the other 3 experienced clearing of nearly half
the skin lesions and a decrease in the substance
and sealing of the remainder during the first
month of therapy (Figures 2, 3). After the initial
month's improvement the latter group has shown
r 
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Fio. 2. 52-year-old white woman with plaque-like psoriasis of 7 years' duration: (a) before treat-
ment, (b) after 14 days of treatment with TA-AITJR, (e) after 28 days of treatment with TA-AzIJR, (d)
after 60 days of treatment with TA-AzUR.
no further decrease in extent of involvement
despite maintenance of drug at the above doses
for 1 to 3 months. No sign of relapse, however,
has occurred during this time.
TA-AzUR therapy was empirically discon-
tinued in 6 patients after varying degrees of
clinical improvement. There has been no sign of
relapse in one patient with exfoliative erythro-
derma and another with plaque-like disease one
month after discontinuing therapy. The remain-
ing 4 patients showed reactivation of disease
shortly after cessation of treatment with gradual
recurrence of psoriatic lesions. Within two weeks,
2 individuals had lesions that were identical in
distribution and in character to the original clini-
cal picture, while the exacerbation in the other 2
patients was of lesser extent than that seen
originally. It appears that the response after
reinstitution of therapy is identical to that noted
during the first course.
Resolution of psoriasis was most rapid during
the administration of the initial large doses of
TA-AzIJR (270 mg/kg/day), and somewhat more
gradual on half that dose (135 mg/kg/day); 70
mg/kg/day failed to control the disease in 2
patients with active disease but has not been
tried as maintenance therapy in arrested cases.
All patients originally presenting with pruritus
experienced complete and lasting relief of this
annoying symptom during the first week of FIG. 3
therapy without relation to extent of objective
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improvement. Several patients reported tempo-
rary increase of pruritus during the first 3 days of
drug administration.
There was neither subjective nor objective
evidence of stomatitis, gastrointestinal, bepatic,
or renal toxicity; skin ulceration or damage to
hair follicles was not encountered nt any time
during the course of the treatment.
Histological Studies
Serial biopsy studies confirmed the clinical
impression of improvement in the psoriatic lesions
after therapy with TA-AzT.JR (Figure 4). At the
time of the first specimens, 4 days after the begin-
ning of treatment, a prominent layer of granular
cells was evident subjacent to a thin normal-
appearing stratum corneum. In the patients with
exfoliative erythroderma, the histological appear-
ance of the epidermis was completely normal
within 10 to 14 days after the start of therapy,
while a mild mononuclear infiltrate in the dermis
and dilatation of the upper dermal capillaries per-
sisted. In the patients with a plaque-like psoriatic
Fm. 4. Histologic sections of sequential biopsy
specimens from adjacent sites of a psoriatic les-
ion. x43. Paticnt with plaque-like psoriasis of 7
years' duration: (a) before treatment, (b) after 21
days of treatment with TA-AzUR, (c) after 35
days of treatment with TA-AzUR, (d) after 70
days of treatment with TA-AzUR.
involvement, biopsy studies during the first
month of treatment showed some shortening of
rete pegs with a decrease in the length of the
dermal-epidermal border. The appearance of the
stratum corneum reverted to norr.I during this
time. As in the other cases, capillary dilatation
and cellular infiltrates were still noticeable in
the dermis after one month of therapy.
Laboratory Studies
Toxicity of TA-AzTJR appeared to be limited
to the hematopoietic system (Figure 5). Complete
blood counts in all patients were normal before
the start of therapy. Those receiving 270 mg/kg/
day for 14 days or more showed a decline in the
reticulocyte count followed by a decrease in the
hematocrit to levels of 32 to 36%. At first, the dose
of TA-AzUR was reduced to 135 mg/kg/day only
after the onset of anemia. Later, when the dose
was decreased as early as 10 days after the start
of therapy, anemia was not observed. Although
patients receiving higher doses for longer periods
of time developed moderate anemia, prompt
reappearance of reticulocytes and gradual return
of the hematocrit to normal levels was observed
upon continuation of therapy at lower doses.
In three patients mild leukopenia was noted with
leukocyte counts in the range of 3500 to 4000
cells/cu mm. No thrombocytopenia was observed.
Ferrokinetic studies revealed elevation of the
serum iron during treatment and delayed clear-
ance of Fe59 from the plasma; the bone marrows
showed mild to moderate hypocellularity with
megaloblastic changes in the late erythroid ele-
ments. The serum uric acid levels, initially higher
than normal in half the patients, decreased in all
during therapy (19). Electroencephalograms,
liver function tests and blood urea nitrogen deter-
minations remained normal during the course of
treatment.
DiscUssiON
The characteristic thickening and scaling of
psoriatic lesions may be regarded as a result of
hyperplasia of the germinative cells of human
epidermis. Abnormally large numbers of mitotie
figures may be identified in the basal cell layer
resulting in an increased rate of turnover of
epidermal cells with subsequent impairment of
normal production of keratin (11, 18, 20). Al-
though the pathological features of psoriasis are
most striking in the epidermis, they are not con-
fined solely to that area. The dilatation of the
dermal capillaries is an integral part of the char-
acteristic histopathology. The relationship of this
aspect of the disease to the etiology and course of
psoriasis is poorly understood (22, 23).
Since neither the locus nor the specific defect
responsible for the entire disease process is
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FIG. 5. Effects of prolonged administration of TA-AzUR on the hematopoietic system
known, therapeutic efforts in psoriasis are di-
rected at the more troublesome manifestations of
the disease—the epidermal abnormalities. Im-
provement of these abnormalities proceeds in the
same fashion regardless of the therapeutic means
employed (11, 24, 25): first there is a reduction
in the number of mitoses in the basal layer, then
a layer of granular cells appears, and finally pro-
duction of a normal stratum corneum ensues. The
unifying factor common to the numerous varie-
ties of treatment known to be effective in psoria-
sis seems to be the capability of the agents to
retard cellular multiplication. It is not known if
this is the result of a direct or an indirect action
on the basal cells or whether some contributing
effect of these agents on the dermis is involved.
Although psoriasis may be extremely disabling
and refractory to treatment, the risks involved
in the use of systemic chemotherapy must be
proportionate to the relatively benign nature of
the process. Because earlier clinical and pharma-
cological studies with AzTJR and its triacetyl
derivative had demonstrated lack of severe
toxicity at doses capable of interfering with
proliferation of certain neoplastic cells (16, 17),
cautious therapeutic trials in patients with
severe and unresponsive psoriasis were initiated.
The development of TA-AzUR, a convenient
orally effective derivative of AzUR, obviates the
need for frequent intravenous injections to main-
tain desired levels of the antimetabolite in the
blood. Both agents exert their effect after con-
version to azauridylic acid (AzUMP) which
competes with orotidylic acid for the enzyme
orotidylie acid decarboxylase thereby blocking
the de novo synthesis of uridylie acid (Figure 6).
Because the synthesis of nucleic acids in cells
capable of utilizing preformed uridine deriva-
tives should not be impaired by this metabolic
blockade, a possible explanation for the selective
toxicity of AzLTR may be inferred. Although evi-
dence that these biochemical pathways are opera-
tive in the germinal cells of psoriatie epidermis
remains to be obtained, studies in human and
canine leukocytes suggest that a greater capacity
to metabolize orotic acid may reflect a greater
dependence of the cell on the de novo pathway
of pyrimidine biosynthesis and an enhanced
susceptibility to the toxic effects of AzUR. Fur-
ther clinical and biochemical correlations will be
necessary to demonstrate whether such quanti-
tative metabolic differences may be exploited to
predict the selection of possible candidates for
therapy.
In the present study, as in earlier clinical trials
in patients with neoplastic disease (16, 17), ad-
ministration of TA-AzUR did not result in severe
toxicity. Even after prolonged administration of
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drug no evidence of stomatitis, gastrointestinal
toxicity, damage to the hair follicles or alopecia
was observed. The turnover time of oral and
gastrointestinal mucosa is of the same order of
magnitude as that of the psoriatic epithelium
and that of the hair matrix is even more rapid
(13). In contrast with other cytotoxic agents used
in psoriasis, the inhibitory effects of TA-AzUR
on epithelial tissues were selectively limited to
areas of disease and did not indiscriminately in-
volve all rapidly growing epithelial structures.
Toxicity with TA-AzUR appeared to be con-
fined to the hematopoietic system and was sus-
pected but not established by earlier short-term
studies (16). A mild to moderate anemia de-
veloped in most of the patients, and was char-
acterized by rcticulocytopenia, reduced utiliza-
tion of iron and megaloblastic change in the
marrow. These changes, which will be reported
in detail elsewhere, were rapidly reversible upon
discontinuation of drug and improved even with
continuation of TA-AzUR at reduced doses.
Three patients demonstrated mild lcukopenia
but no thrombocytopenia was observed.
The fact that TA-AzTJR is effective in psoriasis
is of considerable significance since an insight
into the preferential mode of pyrimidine bio-
synthesis in psoriatic cells may be inferred. Al-
though the response to TA-AzUR may contribute
no further knowledge to the ctiologic basis of the
disease than a similar response in leukemia or
mycosis fungoides, the apparent selective toxicity
for psoriatic cells demonstrated by this anti-
metabolitc offers a therapeutic advantage de-
serving of further investigation.
5UMMARY
Triacetyl-6-azauridinc (TA-AzUR), an orally
administered antimctabolite, produced salutary
effects on the lesions of psoriasis in 10 patients
with disabling disease. The drug inhibits oro-
tidylic acid decarboxylase in the de novo path-
way of pyrimidine metabolism. The major toxic
manifestation of TA-AzUR during prolonged ad-
ministration was mild to moderate anemia,
rapidly reversible upon discontinuation of the
drug or reduction of therapeutic doses. There were
no cases of oral, gastrointestinal or skin ulcera-
tion, and hair loss did not occur. This differential
effect on the reproductive capacities of epithelial
cells suggests that TA-AzUR, at these doses,
exerts a selective inhibitory effect in psoriatic
epidermis without significant toxicity to normal
tissues.
AnDENDUM
An additional four patients who were not in-
cluded in the group reported above were treated
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FIG. 6. Simplified schematic pathways of pyrimidinc biosynthesis. The interrelationship of AzUR
and derivatives and their site of inhibition of the de novo pathway.
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with TA-AzTJR. One, with exfoliative erythro-
derma, had evidence suggesting impaired intesti-
nal absorption. Improvement in his skin lesions
was slight and no hematopoietie changes occurred
despite prolonged oral administration of the drug.
The remaining three had extensive plaque-like
involvement with psoriasis and, in addition to
TA-AzTJR, were treated with topical steroids,
tar and ultraviolet light, and ultraviolet light
alone, respectively. The response of the skin and
hematopoietie system was similar to that of the
patients in the study.
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